diabetes in pregnancy

in review 4 min read Updated 2026-10-15
diabetes in pregnancy

HbA1c ≤7.0% (ideally ≤6.5%) pre-conception, ≤6.5% (ideally ≤6.1%) in pregnancy — malformation risk is set in organogenesis. Pregnancy targets: fasting <5.3, 1 h PP <7.8, 2 h PP <6.7 mmol/L. Insulin is first-line; metformin (± glyburide) acceptable; stop GLP-1 RA, SGLT2i, DPP-4i, other SUs. GDM screen 24–28 wk with 50 g GCT. DKA happens at near-normal glucose. Insulin requirement drops abruptly at delivery.

glycaemic targets (diabetes canada)

measuretarget
fasting / pre-meal<5.3 mmol/L
1 h post-meal<7.8 mmol/L
2 h post-meal<6.7 mmol/L
HbA1c (pregnancy)≤6.5% (ideally ≤6.1% if safe)
CGM (T1DM)time in range 3.5–7.8 mmol/L >70%
intrapartum4.0–7.0 mmol/L (neonatal hypoglycaemia)
  • SMBG ≥4×/d: fasting + 1 h or 2 h after each meal
  • Postprandial glucose drives macrosomia — HbA1c alone is insufficient
  • Hypoglycaemia awareness ↓ in T1 → glucagon at home; driving precautions

pre-existing type 1 / type 2

Pre-conception

  • HbA1c ≤7.0% (ideally ≤6.5%); contraception until achieved
  • Folic acid 1 mg/d pre-conception to 12 wk, then 0.4 mg
  • Retinal exam, uACR + Cr, BP, ± ECG/echo if CV risk
  • Stop: GLP-1 RA, SGLT2i, DPP-4i, non-glyburide SUs, TZDs → insulin ± metformin; statins (primary prevention, when planning pregnancy); ACEi/ARB at positive test (continue until then if nephropathy)
  • Aspirin 81–162 mg qhs from 12–16 wk to 36 wk

During pregnancy

  • T1DM: MDI or pump; CGM (CONCEPTT (2017)); insulin needs fall late T1 (hypoglycaemia) then rise 2–3× by T3
  • T2DM: switch to insulin ± metformin (MiTy (2020)); glyburide only third-line in GDM (declines insulin, metformin fails)
  • BP target <130/80 — see chronic hypertension in pregnancy
  • Retinopathy can progress (rapid glucose lowering, HTN) → exam each trimester if present
  • Nephropathy → ↑ preeclampsia, FGR; quantify baseline proteinuria
  • Foetal echo/detailed anatomy scan if periconception HbA1c elevated

Foetal/neonatal risks: congenital anomalies (cardiac, NTD, caudal regression), miscarriage, stillbirth (3–5×), macrosomia/shoulder dystocia, FGR with vasculopathy, neonatal hypoglycaemia, RDS, hyperbilirubinaemia


gestational diabetes

Screening — 24–28 wk (Diabetes Canada preferred two-step)

testresultinterpretation
50 g GCT (non-fasting, 1 h)<7.8normal
7.8–11.0→ 75 g OGTT
≥11.1GDM — no OGTT needed
75 g OGTT (two-step)fasting ≥5.3, 1 h ≥10.6, 2 h ≥9.0≥1 value = GDM
75 g OGTT (one-step, alternative)fasting ≥5.1, 1 h ≥10.0, 2 h ≥8.5≥1 value = GDM
  • High risk (prior GDM, obesity, PCOS, high-risk ethnicity, prediabetes) → early HbA1c/fasting glucose in T1; HbA1c ≥6.5% = pre-existing diabetes; rescreen at 24–28 wk if negative

Management

  • Nutrition therapy + activity; SMBG QID
  • Not at target in 1–2 wk → insulin: NPH qhs for fasting, rapid-acting with the meals that are high
  • Metformin: alternative if insulin declined/impractical — crosses placenta, ~40% need add-on insulin; long-term offspring data limited
  • Glyburide: add-on to metformin if insulin refused; more neonatal hypoglycaemia; not gliclazide
  • GDM alone ≠ aspirin indication

Postpartum

  • Stop all agents; check glucose before discharge
  • 75 g OGTT 6 wk–6 months postpartum, then HbA1c/fasting glucose every 1–3 y
  • GDM recurrence 30–84%; ~40% develop T2DM by 16 y
  • Breastfeeding ↓ maternal T2DM risk and neonatal hypoglycaemia
exam pattern — which insulin?

GDM, fasting 5.1–5.3 (at target), 1 h post-breakfast 8.2 and post-lunch 7.9, post-dinner 7.3 → prandial rapid-acting insulin with breakfast and lunch only. Match insulin to the specific reading that is out of range.


DKA in pregnancy

  • Occurs at lower glucose (often <11–14 mmol/L) — accelerated ketogenesis, respiratory alkalosis ↓ buffer
  • Triggers: vomiting/HG, infection, steroids for foetal lung maturity, β-agonists, pump failure, insulin omission
  • Check β-hydroxybutyrate + VBG in any diabetic pregnant patient with vomiting or malaise — glucose may be 8–10 mmol/L
  • Management as standard (fluids, insulin, K⁺) + dextrose early to allow insulin; foetal monitoring (abnormal tracing usually resolves with maternal correction — don’t deliver urgently for it) — see DKA management
  • Betamethasone → expect 2–3 d of hyperglycaemia; pre-emptive insulin increase
euglycaemic DKA

T1DM at 25 wk, vomiting, glucose 9.6, HCO₃⁻ 15, ↑ anion gap = DKA until proven otherwise. Foetal mortality is high in DKA.


delivery and postpartum (pre-existing)

  • Delivery 38–39 wk pregestational, 38–40 wk GDM (earlier if complications); IV insulin–dextrose protocol in labour
  • At placenta delivery insulin requirements fall ~50% → restart below pre-pregnancy dose; T1DM must keep basal insulin
  • Breastfeeding ↑ hypoglycaemia (snack before feeds); metformin and glyburide compatible
  • Resume ACEi (enalapril) for nephropathy; resume statin after breastfeeding
  • T1DM: TSH ~3 months postpartum (postpartum thyroiditis)

evidence

  • CONCEPTT (2017) — T1DM, real-time CGM: ↑ time in range, ↓ LGA, neonatal hypoglycaemia, NICU admission (NNT ~6)
  • MiTy (2020) — T2DM, metformin + insulin vs placebo + insulin: no difference in neonatal composite; less maternal weight gain and insulin; fewer LGA but more SGA infants

Prepared 2026-10-15. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction diabetes in pregnancy